These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22286821)

  • 1. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
    Duong U; Kalantar-Zadeh K; Molnar MZ; Zaritsky JJ; Teitelbaum I; Kovesdy CP; Mehrotra R
    Am J Nephrol; 2012; 35(2):198-208. PubMed ID: 22286821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.
    Suttorp MM; Hoekstra T; Rotmans JI; Ott I; Mittelman M; Krediet RT; Dekker FW
    BMC Nephrol; 2013 Sep; 14():200. PubMed ID: 24066978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
    Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of hemoglobin and survival in peritoneal dialysis patients.
    Molnar MZ; Mehrotra R; Duong U; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1973-81. PubMed ID: 21784829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
    Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
    Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
    Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
    Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
    Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
    Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
    Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
    Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.
    Eriguchi R; Taniguchi M; Ninomiya T; Hirakata H; Fujimi S; Tsuruya K; Kitazono T
    J Nephrol; 2015 Apr; 28(2):217-25. PubMed ID: 25080399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study.
    Wan Q; He Y; Zhang W; Wu Q; Xiong Z
    Int Urol Nephrol; 2014 Aug; 46(8):1651-4. PubMed ID: 24114285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis.
    Pérez-García R; Varas J; Cives A; Martín-Malo A; Aljama P; Ramos R; Pascual J; Stuard S; Canaud B; Merello JI;
    Nephrol Dial Transplant; 2018 Apr; 33(4):690-699. PubMed ID: 29036505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.
    Maruyama Y; Yokoyama K; Higuchi C; Sanaka T; Tanaka Y; Sakai K; Kanno Y; Ryuzaki M; Sakurada T; Hosoya T; Nakayama M;
    Ther Apher Dial; 2023 Aug; 27(4):735-741. PubMed ID: 36897071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
    Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
    BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.